AACR22: As post-Covid de­vel­op­ment takes shape, BioN­Tech re­ports first hu­man da­ta for CAR-T/can­cer vac­cine com­bo

NEW OR­LEANS — Con­tin­u­ing to push in­to new fron­tiers fol­low­ing the huge suc­cess of its Covid-19 vac­cine, BioN­Tech re­vealed the first-in-hu­man da­ta for its com­bi­na­tion CAR-T and mR­NA can­cer ther­a­py.

In a Phase I por­tion of a Phase I/II study, the Ger­man biotech re­port­ed that six of 14 evalu­able pa­tients achieved a par­tial re­sponse six weeks af­ter treat­ment, with one ad­vanc­ing to a com­plete re­sponse by Week 18. Four of the re­spons­es came in tes­tic­u­lar can­cer pa­tients, while the oth­er two man­i­fest­ed in in­di­vid­u­als with ovar­i­an can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER